HOME >> BIOLOGY >> NEWS
Other highlights in the May 19 JNCI

Two Studies Examine Safe Three Agent Combination Therapy for HER2-Positive Advanced Breast Cancer

Combinations of docetaxel, cisplatin or carboplatin, and the monoclonal antibody trastuzumab are feasible for the treatment of patients with HER2-positive advanced breast cancer in which tumor response rates are high, according to two new studies.

Human epidermal growth factor receptor 2 (HER2) is overexpressed in the tumors of 20-30% of breast cancer patients and is associated with an increased risk of relapse and death in patients with early-stage breast cancer. In earlier clinical trials, adding trastuzumab, which blocks the effects of HER2, to standard chemotherapy increased both the response rate of patients and survival, but an unacceptable number of patients experienced cardiac dysfunction, including congestive heart disease.

In the first of two studies designed to find safer chemotherapy combinations that include trastuzumab, Mark D. Pegram, M.D., of the University of California, Los Angeles, and colleagues characterized the interactions between trastuzumab and nine chemotherapy drugs commonly used in treating breast cancer in four cell lines that overexpress HER2. They found synergistic interactions of trastuzumab plus carboplatin, 4-hydroxycyclophosphamide, docetaxel, or vinorelbine, which indicated that these were reasonable combinations to test in human clinical trials.

In the second study, a second group of researchers also led by Pegram, conducted two phase II clinical trials to evaluate the combination of docetaxel and trastuzumab with either of two platinum salts, cisplatin or carboplatin. In each trial, the combinations were tested on 62 women with advanced breast cancer that overexpressed HER2. Both combinations had a similar toxicity to docetaxel plus platinum salts alone, and there was a low incidence of cardiac dysfunction. In addition, overall response rates were higher. The combinations are now being tested
'"/>

Contact: Sarah L. Zielinski
jncimedia@oupjournals.org
301-841-1287
Journal of the National Cancer Institute
18-May-2004


Page: 1 2 3 4

Related biology news :

1. Other highlights in the September 1 JNCI
2. Other highlights in the August 18 JNCI
3. Other highlights in the August 4 JNCI
4. Other highlights in the July 7 JNCI
5. Other highlights in the June 16 JNCI
6. Other Highlights in the June 2 JNCI
7. Other highlights in the May 5 JNCI
8. Other highlights of the March 17 issue of JNCI
9. Other highlights in the March 3 issue of JNCI
10. Other highlights in the February 18 issue of JNCI
11. Other highlights in the February 4 issue of JNCI

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/17/2019)... (PRWEB) , ... July 16, 2019 , ... Imagine using ... or to detect bone loss before it causes osteoporosis. For South Dakota School of ... “This is potentially a game-changer in terms of our ability to monitor and prevent ...
(Date:7/9/2019)... ... July 09, 2019 , ... Murrieta Genomics, ... its incubator program. The founder and CEO of Tx Genetic, Helen Harrison, has ... those suffering from epithelial connective tissue disorders. , “We are pleased and excited ...
(Date:7/5/2019)... ... July 05, 2019 , ... ... bring its patented Tractus™ Platform to governments around the world. , Powered ... technology and point of care solutions to operating theatres worldwide to address new ...
Breaking Biology News(10 mins):
(Date:7/9/2019)... ... 2019 , ... Today, at the BIO World Congress on Industrial ... (NCGA) announced the winners of the Consider Corn Challenge II. Three winners were chosen, ... to produce biobased materials. , “Corn is a sustainable, abundant and affordable ...
(Date:6/18/2019)... ... June 18, 2019 , ... Personalized Stem Cells, Inc (“PSC”), ... to the FDA for use of a person’s own adipose-derived stem cells to treat ... in the knee. This IND is the first of several planned clinical trials ...
(Date:6/11/2019)... ... June 11, 2019 , ... Mytonomy, ... a national leader in opioid treatment, announced today they are partnering to combat ... Mytonomy recently deployed its virtual care platform at the Mayo Clinic to drive ...
(Date:5/31/2019)... Redwood City, California (PRWEB) , ... ... ... received allowance of our patent applications from the USPTO providing proprietary interest ... SYSTEM AND METHOD FOR SLEEP DISORDER DIAGNOSIS AND TREATMENT… extends Somnology’s IP ...
Breaking Biology Technology:
Cached News: